GSA Capital Partners LLP Purchases 232,087 Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

GSA Capital Partners LLP lifted its holdings in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) by 194.9% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 351,193 shares of the biotechnology company's stock after purchasing an additional 232,087 shares during the period. GSA Capital Partners LLP owned about 0.22% of Ironwood Pharmaceuticals worth $1,447,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of IRWD. CWM LLC grew its stake in shares of Ironwood Pharmaceuticals by 55.1% during the 2nd quarter. CWM LLC now owns 6,600 shares of the biotechnology company's stock valued at $43,000 after buying an additional 2,345 shares during the period. Diversified Trust Co acquired a new stake in shares of Ironwood Pharmaceuticals in the 3rd quarter valued at about $52,000. Legacy Capital Group California Inc. acquired a new stake in shares of Ironwood Pharmaceuticals in the 3rd quarter valued at about $59,000. GAMMA Investing LLC grew its position in shares of Ironwood Pharmaceuticals by 344.1% during the 2nd quarter. GAMMA Investing LLC now owns 10,526 shares of the biotechnology company's stock valued at $69,000 after buying an additional 8,156 shares during the last quarter. Finally, First Dallas Securities Inc. bought a new stake in shares of Ironwood Pharmaceuticals during the 2nd quarter valued at about $73,000.

Wall Street Analysts Forecast Growth

Several research analysts have commented on IRWD shares. Leerink Partners started coverage on shares of Ironwood Pharmaceuticals in a research report on Monday, September 9th. They issued a "market perform" rating and a $5.00 target price for the company. Leerink Partnrs upgraded shares of Ironwood Pharmaceuticals to a "hold" rating in a research report on Monday, September 9th. Wells Fargo & Company decreased their target price on shares of Ironwood Pharmaceuticals from $14.00 to $12.00 and set an "overweight" rating for the company in a research report on Friday, August 9th. Capital One Financial cut shares of Ironwood Pharmaceuticals from an "overweight" rating to an "equal weight" rating and decreased their target price for the stock from $12.00 to $4.00 in a research report on Thursday, August 8th. Finally, StockNews.com cut shares of Ironwood Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Tuesday. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $10.40.

Ironwood Pharmaceuticals Trading Down 0.5 %

IRWD stock traded down $0.02 during midday trading on Thursday, reaching $4.28. The company had a trading volume of 429,414 shares, compared to its average volume of 2,915,434. The company has a market capitalization of $683.68 million, a P/E ratio of -145.33 and a beta of 0.47. The company has a 50 day moving average of $4.29 and a two-hundred day moving average of $5.52. Ironwood Pharmaceuticals, Inc. has a 1 year low of $3.79 and a 1 year high of $15.70.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last released its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.02 earnings per share for the quarter, missing analysts' consensus estimates of $0.09 by ($0.07). The business had revenue of $91.60 million for the quarter, compared to the consensus estimate of $91.22 million. Ironwood Pharmaceuticals had a negative net margin of 0.65% and a negative return on equity of 0.96%. The firm's revenue for the quarter was down 19.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.12 EPS. On average, sell-side analysts anticipate that Ironwood Pharmaceuticals, Inc. will post 0.1 earnings per share for the current year.

Ironwood Pharmaceuticals Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.